KR20160006215A - 시르투인 조절제로서의 치환된 가교 우레아 유사체 - Google Patents

시르투인 조절제로서의 치환된 가교 우레아 유사체 Download PDF

Info

Publication number
KR20160006215A
KR20160006215A KR1020157034916A KR20157034916A KR20160006215A KR 20160006215 A KR20160006215 A KR 20160006215A KR 1020157034916 A KR1020157034916 A KR 1020157034916A KR 20157034916 A KR20157034916 A KR 20157034916A KR 20160006215 A KR20160006215 A KR 20160006215A
Authority
KR
South Korea
Prior art keywords
sirtuin
compound
mmol
methanopyrido
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157034916A
Other languages
English (en)
Korean (ko)
Inventor
찰스 에이. 블룸
크리스토퍼 올만
브루스 쥐. 스츠크체판키에위크츠
리차드 다나 콜드웰
레베카 카조봉
브라이언 에이취. 화이트
로버트 비. 페니
카르스텐 코페치
제레미 에스. 디쉬
푸이 이 엔쥐
라이언 마이클 폭스
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20160006215A publication Critical patent/KR20160006215A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157034916A 2013-05-13 2014-05-13 시르투인 조절제로서의 치환된 가교 우레아 유사체 Ceased KR20160006215A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822758P 2013-05-13 2013-05-13
US61/822,758 2013-05-13
PCT/US2014/037767 WO2014186313A1 (en) 2013-05-13 2014-05-13 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
KR20160006215A true KR20160006215A (ko) 2016-01-18

Family

ID=53264426

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157034916A Ceased KR20160006215A (ko) 2013-05-13 2014-05-13 시르투인 조절제로서의 치환된 가교 우레아 유사체
KR1020177016322A Withdrawn KR20170084274A (ko) 2013-05-13 2015-11-19 시르투인 조정제로서의 치환된 가교된 우레아 유사체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177016322A Withdrawn KR20170084274A (ko) 2013-05-13 2015-11-19 시르투인 조정제로서의 치환된 가교된 우레아 유사체

Country Status (11)

Country Link
US (4) US9765075B2 (enExample)
EP (2) EP2997029B1 (enExample)
JP (2) JP6376707B2 (enExample)
KR (2) KR20160006215A (enExample)
CN (2) CN105392788B (enExample)
AU (3) AU2014265671B2 (enExample)
BR (2) BR112015028613A2 (enExample)
CA (2) CA2912683A1 (enExample)
ES (1) ES2718550T3 (enExample)
RU (2) RU2015153061A (enExample)
WO (1) WO2014186313A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624184B2 (en) * 2013-04-04 2017-04-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6376707B2 (ja) * 2013-05-13 2018-08-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節剤としての置換架橋尿素類似体
JP2016079173A (ja) * 2014-10-15 2016-05-16 日本合成化学工業株式会社 新規ピリジン系化合物、それを用いたアニオン硬化性化合物用硬化剤、硬化性組成物及び硬化物
CN107207520A (zh) * 2014-11-19 2017-09-26 葛兰素史密斯克莱知识产权（第2 号）有限公司 作为沉默调节蛋白调节剂的取代的桥环脲类似物
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111511723A (zh) * 2017-08-21 2020-08-07 米可如比奥提克斯有限公司 用作抗菌剂的代谢稳定的n-酰基氨基噁二唑
JP7156207B2 (ja) * 2019-08-07 2022-10-19 株式会社島津製作所 糖ペプチド解析装置
CN112759593A (zh) * 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用
CN112094362B (zh) * 2020-09-29 2022-04-12 四川大学华西医院 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用
CN112645805A (zh) * 2020-12-23 2021-04-13 北京理工大学 一种由温勒伯酰胺制备均苯三甲醛的方法
CN115518062B (zh) * 2022-09-02 2024-03-22 成都大学 Phellopterin在制备用于治疗STAT信号通路介导的相关疾病药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE4424484A1 (de) * 1994-07-12 1996-01-18 Bayer Ag Azofarbstoffe, deren Herstellung und Verwendung
EP1781300A1 (en) * 2004-07-16 2007-05-09 ProteoSys AG Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006094248A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Aryl-substituted cyclic sirtuin modulators
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
ATE488232T1 (de) 2006-09-04 2010-12-15 Univ Dundee P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
CN101952286A (zh) * 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
EP2350051A4 (en) 2008-10-29 2012-05-30 Sirtris Pharmaceuticals Inc PYRIDINE, BICYCLIC PYRIDINE AND ITS ANALOGS AS SIRTUINE MODULATORS
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
WO2011059839A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
US20140288052A1 (en) 2011-10-20 2014-09-25 GlaxoSmithKline, LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2016081692A2 (en) 2014-11-19 2016-05-26 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
JP6376707B2 (ja) 2013-05-13 2018-08-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節剤としての置換架橋尿素類似体

Also Published As

Publication number Publication date
AU2017204176A1 (en) 2017-07-13
WO2014186313A1 (en) 2014-11-20
AU2015349912A1 (en) 2017-06-01
RU2015153061A3 (enExample) 2018-03-21
AU2017204176B2 (en) 2018-07-26
JP6833686B2 (ja) 2021-02-24
AU2014265671A8 (en) 2016-06-16
CA2912683A1 (en) 2014-11-20
US9765075B2 (en) 2017-09-19
US20150152108A1 (en) 2015-06-04
RU2017120859A (ru) 2018-12-20
JP6376707B2 (ja) 2018-08-22
EP2997029A4 (en) 2017-05-24
WO2014186313A8 (en) 2015-12-23
EP2997029B1 (en) 2019-01-09
US10590135B2 (en) 2020-03-17
JP2017536364A (ja) 2017-12-07
AU2014265671B2 (en) 2017-04-06
JP2016518448A (ja) 2016-06-23
EP3221312A2 (en) 2017-09-27
US20180044338A1 (en) 2018-02-15
EP2997029A1 (en) 2016-03-23
CN105392788A (zh) 2016-03-09
US20170355697A1 (en) 2017-12-14
US9834558B2 (en) 2017-12-05
CN107207496A (zh) 2017-09-26
US20160083386A1 (en) 2016-03-24
BR112015028613A2 (pt) 2017-07-25
ES2718550T3 (es) 2019-07-02
CA2975291A1 (en) 2016-05-26
BR112017010592A2 (pt) 2018-03-06
RU2015153061A (ru) 2017-06-15
CN105392788B (zh) 2018-10-23
EP3221312A4 (en) 2018-05-30
AU2014265671A1 (en) 2015-11-26
KR20170084274A (ko) 2017-07-19

Similar Documents

Publication Publication Date Title
JP6376707B2 (ja) サーチュイン調節剤としての置換架橋尿素類似体
JP6073343B2 (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
RU2550821C2 (ru) Бициклические пиридины и аналоги в качестве модуляторов сиртуина
KR20140077965A (ko) 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
KR20110128908A (ko) 시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체
KR20140077964A (ko) 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
KR20170083135A (ko) 시르투인 조정제로서의 치환된 가교된 우레아 유사체
WO2016081692A2 (en) Substituted bridged urea analogs as sirtuin modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190510

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201109

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210521

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201109

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I